{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:20:46Z","timestamp":1790742046937,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T00:00:00Z","timestamp":1697068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T00:00:00Z","timestamp":1697068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006313","name":"Barncancerfonden","doi-asserted-by":"publisher","award":["PR2020-0023"],"award-info":[{"award-number":["PR2020-0023"]}],"id":[{"id":"10.13039\/501100006313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2020-01377"],"award-info":[{"award-number":["2020-01377"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["CAN 20 0191"],"award-info":[{"award-number":["CAN 20 0191"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["CAN 21 1534"],"award-info":[{"award-number":["CAN 21 1534"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Stiftelsen Ulf Lundahls minnesfond"},{"DOI":"10.13039\/501100007051","name":"Uppsala University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Molecular radiotherapy is a treatment modality that is highly suitable for targeting micrometastases and [<jats:sup>177<\/jats:sup>Lu]Lu-DOTATATE is currently being explored as a potential novel treatment option for high-risk neuroblastoma. p53 is a key player in the proapoptotic signalling in response to radiation-induced DNA damage and is therefore a potential target for radiosensitisation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This study investigated the use of the p53 stabilising peptide VIP116 and [<jats:sup>177<\/jats:sup>Lu]Lu-DOTATATE, either alone or in combination, for treatment of neuroblastoma tumour xenografts in mice. Initially, the uptake of [<jats:sup>177<\/jats:sup>Lu]Lu-DOTATATE in the tumours was confirmed, and the efficacy of VIP116 as a monotherapy was evaluated. Subsequently, mice with neuroblastoma tumour xenografts were treated with placebo, VIP116, [<jats:sup>177<\/jats:sup>Lu]Lu-DOTATATE or a combination of both agents.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The results demonstrated that monotherapy with either VIP116 or [<jats:sup>177<\/jats:sup>Lu]Lu-DOTATATE significantly prolonged median survival compared to the placebo group (90 and 96.5 days vs. 50.5 days, respectively). Notably, the combination treatment further improved median survival to over 120 days. Furthermore, the combination group exhibited the highest percentage of complete remission, corresponding to a twofold increase compared to the placebo group. Importantly, none of the treatments induced significant nephrotoxicity. Additionally, the therapies affected various molecular targets involved in critical processes such as apoptosis, hypoxia and angiogenesis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In conclusion, the combination of VIP116 and [<jats:sup>177<\/jats:sup>Lu]Lu-DOTATATE presents a promising novel treatment approach for neuroblastoma. These findings hold potential to advance research efforts towards a potential cure for this vulnerable patient population.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00259-023-06462-3","type":"journal-article","created":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T10:02:18Z","timestamp":1697104938000},"page":"768-778","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["p53 stabilisation potentiates [177Lu]Lu-DOTATATE treatment in neuroblastoma xenografts"],"prefix":"10.1007","volume":"51","author":[{"given":"Hanna","family":"Berglund","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Lundsten","family":"Salomonsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tabassom","family":"Mohajershojai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Jose Ferrer","family":"Gago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4662-3142","authenticated-orcid":false,"given":"Marika","family":"Nestor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,12]]},"reference":[{"key":"6462_CR1","doi-asserted-by":"publisher","first-page":"836230","DOI":"10.3389\/fped.2022.836230","volume":"10","author":"F Sundquist","year":"2022","unstructured":"Sundquist F, Georgantzi K, Jarvis KB, Brok J, Koskenvuo M, Rascon J, et al. A Phase II trial of a personalized, dose-intense administration schedule of (177)lutetium-DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma-LuDO-N. Front Pediatr. 2022;10:836230. https:\/\/doi.org\/10.3389\/fped.2022.836230.","journal-title":"Front Pediatr."},{"key":"6462_CR2","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/nrclinonc.2014.168","volume":"11","author":"GM Brodeur","year":"2014","unstructured":"Brodeur GM, Bagatell R. Mechanisms of neuroblastoma regression. Nat Rev Clin Oncol. 2014;11:704\u201313. https:\/\/doi.org\/10.1038\/nrclinonc.2014.168.","journal-title":"Nat Rev Clin Oncol."},{"key":"6462_CR3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1136\/jcp.57.1.14","volume":"57","author":"SA Burchill","year":"2004","unstructured":"Burchill SA. Micrometastases in neuroblastoma: are they clinically important? J Clin Pathol. 2004;57:14\u201320. https:\/\/doi.org\/10.1136\/jcp.57.1.14.","journal-title":"J Clin Pathol."},{"key":"6462_CR4","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3390\/cancers13010150","volume":"13","author":"LMJ van Zogchel","year":"2021","unstructured":"van Zogchel LMJ, Zappeij-Kannegieter L, Javadi A, Lugtigheid M, Gelineau NU, Lak NSM, et al. Specific and sensitive detection of neuroblastoma mRNA markers by multiplex RT-qPCR. Cancers. 2021;13:150. https:\/\/doi.org\/10.3390\/cancers13010150.","journal-title":"Cancers."},{"key":"6462_CR5","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1038\/nbt1218-1125","volume":"36","author":"E Dolgin","year":"2018","unstructured":"Dolgin E. Radioactive drugs emerge from the shadows to storm the market. Nature Biotechnol. 2018;36:1125\u20137. https:\/\/doi.org\/10.1038\/nbt1218-1125.","journal-title":"Nature Biotechnol."},{"key":"6462_CR6","doi-asserted-by":"publisher","first-page":"20170969","DOI":"10.1259\/bjr.20170969","volume":"91","author":"JR Ballinger","year":"2018","unstructured":"Ballinger JR. Theranostic radiopharmaceuticals: established agents in current use. Br J Radiol. 2018;91:20170969. https:\/\/doi.org\/10.1259\/bjr.20170969.","journal-title":"Br J Radiol."},{"key":"6462_CR7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s13402-014-0194-4","volume":"38","author":"LH Mammatas","year":"2015","unstructured":"Mammatas LH, Verheul HM, Hendrikse NH, Yaqub M, Lammertsma AA, der Houven M-v, van Oordt CW. Molecular imaging of targeted therapies with positron emission tomography: the visualization of personalized cancer care. Cell Oncol (Dordr). 2015;38:49\u201364. https:\/\/doi.org\/10.1007\/s13402-014-0194-4.","journal-title":"Cell Oncol (Dordr)."},{"key":"6462_CR8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1053\/j.semnuclmed.2009.12.001","volume":"40","author":"SE Pool","year":"2010","unstructured":"Pool SE, Krenning EP, Koning GA, van Eijck CH, Teunissen JJ, Kam B, et al. Preclinical and clinical studies of peptide receptor radionuclide therapy. Semin Nucl Med. 2010;40:209\u201318. https:\/\/doi.org\/10.1053\/j.semnuclmed.2009.12.001.","journal-title":"Semin Nucl Med."},{"key":"6462_CR9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0167-0115(99)00121-4","volume":"88","author":"AR Albers","year":"2000","unstructured":"Albers AR, O'Dorisio MS, Balster DA, Caprara M, Gosh P, Chen F, et al. Somatostatin receptor gene expression in neuroblastoma. Regulat Peptides. 2000;88:61\u201373. https:\/\/doi.org\/10.1016\/S0167-0115(99)00121-4.","journal-title":"Regulat Peptides."},{"key":"6462_CR10","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1007\/s00259-020-04741-x","volume":"47","author":"JE Gains","year":"2020","unstructured":"Gains JE, Moroz V, Aldridge MD, Wan S, Wheatley K, Laidler J, et al. A phase IIa trial of molecular radiotherapy with 177-lutetium DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma. Eur J Nuclear Med Molecul Imag. 2020;47:2348\u201357. https:\/\/doi.org\/10.1007\/s00259-020-04741-x.","journal-title":"Eur J Nuclear Med Molecul Imag."},{"key":"6462_CR11","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/35042675","volume":"408","author":"B Vogelstein","year":"2000","unstructured":"Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408:307\u201310. https:\/\/doi.org\/10.1038\/35042675.","journal-title":"Nature."},{"key":"6462_CR12","doi-asserted-by":"publisher","unstructured":"Lane DP, Cheok CF, Lain S. p53-based cancer therapy. Cold Spring Harbor Perspec Bio. 2010:2. https:\/\/doi.org\/10.1101\/cshperspect.a001222.","DOI":"10.1101\/cshperspect.a001222"},{"key":"6462_CR13","doi-asserted-by":"publisher","first-page":"6457","DOI":"10.1039\/c9sc01456j","volume":"10","author":"TY Yuen","year":"2019","unstructured":"Yuen TY, Brown CJ, Xue Y, Tan YS, Ferrer Gago FJ, Lee XE, et al. Stereoisomerism of stapled peptide inhibitors of the p53-Mdm2 interaction: an assessment of synthetic strategies and activity profiles. Chem Sci. 2019;10:6457\u201366. https:\/\/doi.org\/10.1039\/c9sc01456j.","journal-title":"Chem Sci."},{"key":"6462_CR14","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1002\/ijc.32058","volume":"144","author":"L Chen","year":"2019","unstructured":"Chen L, Pastorino F, Berry P, Bonner J, Kirk C, Wood KM, et al. Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma. Int J Cancer. 2019;144:3146\u201359. https:\/\/doi.org\/10.1002\/ijc.32058.","journal-title":"Int J Cancer."},{"key":"6462_CR15","doi-asserted-by":"publisher","first-page":"9401","DOI":"10.1021\/acs.jmedchem.3c00623","volume":"66","author":"V Guerlavais","year":"2023","unstructured":"Guerlavais V, Sawyer TK, Carvajal L, Chang YS, Graves B, Ren JG, et al. Discovery of sulanemadlin (ALRN-6924), the first cell-permeating, stabilized alpha-helical peptide in clinical development. J Med Chem. 2023;66:9401\u201317. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c00623.","journal-title":"J Med Chem."},{"key":"6462_CR16","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s11307-016-1018-x","volume":"19","author":"C Wetz","year":"2017","unstructured":"Wetz C, Apostolova I, Steffen IG, Hofheinz F, Furth C, Kupitz D, et al. Predictive value of asphericity in pretherapeutic [111In]DTPA-octreotide SPECT\/CT for response to peptide receptor radionuclide therapy with [177Lu]DOTATATE. Molecular Imag Bio. 2017;19:437\u201345. https:\/\/doi.org\/10.1007\/s11307-016-1018-x.","journal-title":"Molecular Imag Bio."},{"key":"6462_CR17","doi-asserted-by":"publisher","first-page":"102924","DOI":"10.1016\/j.critrevonc.2020.102924","volume":"149","author":"Q Zhao","year":"2020","unstructured":"Zhao Q, Liu Y, Zhang Y, Meng L, Wei J, Wang B, et al. Role and toxicity of radiation therapy in neuroblastoma patients: a literature review. Crit Rev Oncol Hematol. 2020;149:102924. https:\/\/doi.org\/10.1016\/j.critrevonc.2020.102924.","journal-title":"Crit Rev Oncol Hematol."},{"key":"6462_CR18","doi-asserted-by":"publisher","first-page":"292","DOI":"10.2967\/jnmt.119.237354","volume":"48","author":"A Adnan","year":"2020","unstructured":"Adnan A, Basu S. Combined 177Lu-DOTATATE Peptide receptor radionuclide therapy and platinum-based chemotherapy in recurrent, metastatic sinonasal neuroendocrine carcinoma: a promising therapeutic option. J Nuclear Med Technol. 2020;48:292\u20134. https:\/\/doi.org\/10.2967\/jnmt.119.237354.","journal-title":"J Nuclear Med Technol."},{"key":"6462_CR19","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.3892\/ijo.2019.4888","volume":"55","author":"S Lundsten","year":"2019","unstructured":"Lundsten S, Spiegelberg D, Stenerl\u00f6w B, Nestor M. The HSP90 inhibitor onalespib potentiates 177Lu-DOTATATE therapy in neuroendocrine tumor cells. Int J Oncol. 2019;55:1287\u201395. https:\/\/doi.org\/10.3892\/ijo.2019.4888.","journal-title":"Int J Oncol."},{"key":"6462_CR20","doi-asserted-by":"publisher","unstructured":"Lundsten S, Berglund H, Jha P, Krona C, Hariri M, Nelander S, et al. p53-Mediated radiosensitization of (177)Lu-DOTATATE in neuroblastoma tumor spheroids. Biomolecules. 2021:11. https:\/\/doi.org\/10.3390\/biom11111695.","DOI":"10.3390\/biom11111695"},{"key":"6462_CR21","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.3892\/ijo.32.5.1011","volume":"32","author":"R Cuperus","year":"2008","unstructured":"Cuperus R, Tytgat GAM, Leen R, Brites P, Bras J, Caron HN, et al. Pleiotropic effects of fenretinide in neuroblastoma cell lines and multicellular tumor spheroids. Int J Oncol. 2008;32:1011\u20139. https:\/\/doi.org\/10.3892\/ijo.32.5.1011.","journal-title":"Int J Oncol."},{"key":"6462_CR22","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1007\/s00259-019-04673-1","volume":"47","author":"S Lundsten","year":"2020","unstructured":"Lundsten S, Spiegelberg D, Raval NR, Nestor M. The radiosensitizer Onalespib increases complete remission in (177)Lu-DOTATATE-treated mice bearing neuroendocrine tumor xenografts. Eur J Nucl Med Mol Imag. 2020;47:980\u201390. https:\/\/doi.org\/10.1007\/s00259-019-04673-1.","journal-title":"Eur J Nucl Med Mol Imag."},{"key":"6462_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nucmedbio.2021.06.006","volume":"102-103","author":"L Geenen","year":"2021","unstructured":"Geenen L, Nonnekens J, Konijnenberg M, Baatout S, De Jong M, Aerts A. Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [(177)Lu]Lu-DOTA-TATE for the treatment of neuroendocrine tumours. Nucl Med Biol. 2021;102-103:1\u201311. https:\/\/doi.org\/10.1016\/j.nucmedbio.2021.06.006.","journal-title":"Nucl Med Biol."},{"key":"6462_CR24","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/MPH.0000000000000411","volume":"38","author":"G Kong","year":"2016","unstructured":"Kong G, Hofman MS, Murray WK, Wilson S, Wood P, Downie P, et al. Initial experience with gallium-68 DOTA-Octreotate PET\/CT and peptide receptor radionuclide therapy for pediatric patients with refractory metastatic neuroblastoma. J Ped Hematology\/Oncol. 2016;38:87\u201396. https:\/\/doi.org\/10.1097\/MPH.0000000000000411.","journal-title":"J Ped Hematology\/Oncol."},{"key":"6462_CR25","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0304-3835(03)00088-0","volume":"197","author":"DA Tweddle","year":"2003","unstructured":"Tweddle DA, Pearson ADJ, Haber M, Norris MD, Xue C, Flemming C, et al. The p53 pathway and its inactivation in neuroblastoma. Cancer Lett. 2003;197:93\u20138. https:\/\/doi.org\/10.1016\/S0304-3835(03)00088-0.","journal-title":"Cancer Lett."},{"key":"6462_CR26","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/j.chembiol.2016.09.013","volume":"23","author":"W Senkowski","year":"2016","unstructured":"Senkowski W, Jarvius M, Rubin J, Lengqvist J, Gustafsson MG, Nygren P, et al. Large-scale gene expression profiling platform for identification of context-dependent drug responses in multicellular tumor spheroids. Cell Chem Biol. 2016;23:1428\u201338. https:\/\/doi.org\/10.1016\/j.chembiol.2016.09.013.","journal-title":"Cell Chem Biol."},{"key":"6462_CR27","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1186\/s12885-021-08551-8","volume":"21","author":"A Romiani","year":"2021","unstructured":"Romiani A, Spetz J, Shubbar E, Lind DE, Hallberg B, Palmer RH, et al. Neuroblastoma xenograft models demonstrate the therapeutic potential of (177)Lu-octreotate. BMC Cancer. 2021;21:950. https:\/\/doi.org\/10.1186\/s12885-021-08551-8.","journal-title":"BMC Cancer."},{"key":"6462_CR28","unstructured":"Jax.org. 000646 \u2013 A\/J. The Jackson Laboratory; 2018."},{"key":"6462_CR29","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1158\/2326-6066.CIR-13-0067","volume":"2","author":"L Sandin","year":"2014","unstructured":"Sandin L, Orlova A, Gustafsson E, Ellmark P, Tolmachev V, T\u00f6tterman T, et al. Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer. Cancer Immunol Res. 2014;2:80. https:\/\/doi.org\/10.1158\/2326-6066.CIR-13-0067.","journal-title":"Cancer Immunol Res."},{"key":"6462_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2022.128725","volume":"66","author":"Z Zhou","year":"2022","unstructured":"Zhou Z, Zalutsky MR, Chitneni SK. Stapled peptides as scaffolds for developing radiotracers for intracellular targets: preliminary evaluation of a radioiodinated MDM2-binding stapled peptide in the SJSA-1 osteosarcoma model. Bioorg Med Chem Lett. 2022;66:128725. https:\/\/doi.org\/10.1016\/j.bmcl.2022.128725.","journal-title":"Bioorg Med Chem Lett."},{"key":"6462_CR31","doi-asserted-by":"publisher","first-page":"5084","DOI":"10.1158\/0008-5472.Can-18-0440","volume":"78","author":"D Spiegelberg","year":"2018","unstructured":"Spiegelberg D, Mortensen AC, Lundsten S, Brown CJ, Lane DP, Nestor M. The MDM2\/MDMX-p53 antagonist PM2 radiosensitizes wild-type p53 tumors. Cancer Res. 2018;78:5084\u201393. https:\/\/doi.org\/10.1158\/0008-5472.Can-18-0440.","journal-title":"Cancer Res."},{"key":"6462_CR32","doi-asserted-by":"publisher","first-page":"5236","DOI":"10.1158\/1078-0432.CCR-21-0715","volume":"27","author":"MN Saleh","year":"2021","unstructured":"Saleh MN, Patel MR, Bauer TM, Goel S, Falchook GS, Shapiro GI, et al. Phase 1 trial of ALRN-6924, a dual inhibitor of MDMX and MDM2, in patients with solid tumors and lymphomas bearing wild-type TP53. Clin Cancer Res. 2021;27:5236\u201347. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0715.","journal-title":"Clin Cancer Res."},{"key":"6462_CR33","first-page":"1579","volume":"34","author":"D Leveque","year":"2014","unstructured":"Leveque D. Subcutaneous administration of anticancer agents. Anticancer Research. 2014;34:1579\u201386.","journal-title":"Anticancer Research."},{"key":"6462_CR34","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3390\/biomedicines8110471","volume":"8","author":"P Garbati","year":"2020","unstructured":"Garbati P, Barbieri R, Cangelosi D, Zanon C, Costa D, Eva A, et al. MCM2 and carbonic anhydrase 9 are novel potential targets for neuroblastoma pharmacological treatment. Biomed. 2020;8:471. https:\/\/doi.org\/10.3390\/biomedicines8110471.","journal-title":"Biomed."},{"key":"6462_CR35","doi-asserted-by":"publisher","unstructured":"Ward C, Meehan J, Gray M, Kunkler IH, Langdon SP, Argyle DJ. Carbonic anhydrase IX (CAIX), cancer, and radiation responsiveness. Metabolites. 2018:8. https:\/\/doi.org\/10.3390\/metabo8010013.","DOI":"10.3390\/metabo8010013"},{"key":"6462_CR36","doi-asserted-by":"publisher","first-page":"8628","DOI":"10.1038\/sj.onc.1207232","volume":"22","author":"S Wang","year":"2003","unstructured":"Wang S, El-Deiry WS. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene. 2003;22:8628\u201333. https:\/\/doi.org\/10.1038\/sj.onc.1207232.","journal-title":"Oncogene."},{"key":"6462_CR37","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1038\/bjc.2013.636","volume":"109","author":"A Meijer","year":"2013","unstructured":"Meijer A, Kruyt FA, van der Zee AG, Hollema H, Le P, ten Hoor KA, et al. Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL. Br J Cancer. 2013;109:2685\u201395. https:\/\/doi.org\/10.1038\/bjc.2013.636.","journal-title":"Br J Cancer."},{"key":"6462_CR38","doi-asserted-by":"publisher","first-page":"e12577","DOI":"10.1111\/cpr.12577","volume":"52","author":"MW Lee","year":"2019","unstructured":"Lee MW, Kim DS, Kim HR, Park HJ, Lee JW, Sung KW, et al. Inhibition of N-myc expression sensitizes human neuroblastoma IMR-32 cells expressing caspase-8 to TRAIL. Cell Prolif. 2019;52:e12577. https:\/\/doi.org\/10.1111\/cpr.12577.","journal-title":"Cell Prolif."},{"key":"6462_CR39","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.ijrobp.2020.03.003","volume":"107","author":"EJ Kim","year":"2020","unstructured":"Kim EJ, Lee H, Lee YJ, Sonn JK, Lim YB. Ionizing radiation regulates vascular endothelial growth factor-A transcription in cultured human vascular endothelial cells via the PERK\/eIF2\u03b1\/ATF4 pathway. Int J Radiat Oncol Biol Phys. 2020;107:563\u201370. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.03.003.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"6462_CR40","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1038\/cdd.2013.12","volume":"20","author":"M Farhang Ghahremani","year":"2013","unstructured":"Farhang Ghahremani M, Goossens S, Nittner D, Bisteau X, Bartunkova S, Zwolinska A, et al. p53 promotes VEGF expression and angiogenesis in the absence of an intact p21-Rb pathway. Cell Death Differ. 2013;20:888\u201397. https:\/\/doi.org\/10.1038\/cdd.2013.12.","journal-title":"Cell Death Differ."}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06462-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-023-06462-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06462-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T09:04:08Z","timestamp":1705568648000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-023-06462-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,12]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["6462"],"URL":"https:\/\/doi.org\/10.1007\/s00259-023-06462-3","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,12]]},"assertion":[{"value":"21 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report no relevant conflicts of interest for the submitted work. David P. Lane has received support from Merck, Ipsen and Asian. David P. Lane is involved in a collaborative project with Merck on macrocyclic peptides and have a patent issued (WO2014055039A1) on Peptides and Methods for Treating Cancer. Marika Nestor is a co-founder and shareholder of Akiram Therapeutics. The funders had no role in the design of the study; in the collection, analyses or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}